Technology
Stoneridge Reports Second Quarter 2026 Results
Published
2 months agoon
By
Strengthening Demand & Expense Control Underpin 2Q Performance
NOVI, Mich., Aug. 5, 2026 /PRNewswire/ — Stoneridge, Inc. (NYSE: SRI) today announced financial results for the second quarter ended June 30, 2026.
2026 Second Quarter Highlights:
Sales growth of 15.1% YoY to $181.4 millionRecord quarterly MirrorEye revenue of ~$37 million (+39% YoY)Record quarterly revenue for Stoneridge Brazil of $20.5 millionNet loss from continuing operations of $5.3 million, or $0.19 per share; improved from a net loss of $11.1 million, or $0.40 per share, in the prior yearAdjusted EBITDA of $5.5 million; best quarterly performance in 24 monthsReaffirming 2026 guidance ranges
“Our second quarter performance reflects disciplined execution of our strategy as we improve our cost structure and focus our resources on the opportunities that will drive long-term value,” said Natalia Noblet, president and chief executive officer. “In Brazil, our strategic shift toward high-value OEM programs continues to position the business for more sustainable, profitable growth. With strong execution across the business, we remain confident in our strategy and are reaffirming our full-year guidance for 2026.”
The exhibits attached hereto provide reconciliation details on normalizing adjustments of non-GAAP financial measures used in this press release.
Second Quarter Results & Commentary
(in millions, except percentages and per share data)
Results
Three Months Ended June 30,
2026
%
2026
2025
Change
Net Sales
$ 181.4
$ 157.5
15.1 %
Gross Profit
36.8
36.3
1.3 %
Gross Margin %
20.3 %
23.1 %
277 bps
Income (loss) from Operations
(1.2)
(4.2)
71.7 %
Income (loss) before taxes from continuing operations
(2.7)
(9.6)
71.6 %
Provision for income taxes from continuing operations
2.6
1.5
65.6 %
Net Income (loss) from continuing operations
(5.3)
(11.1)
52.6 %
Net Income (loss) per diluted common share from
continuing operations
(0.19)
(0.40)
53.4 %
Weighted-average common shares outstanding
28.2
27.8
1.6 %
Adjusted consolidated EBITDA
$ 5.5
$ 0.8
578.5 %
Adjusted consolidated EBITDA %
3.0 %
0.5 %
251 bps
Consolidated net sales from continuing operations of $181.4 million increased 15.1% YoY. On a core basis, excluding favorable currency translation of $4.4 million and Mexico Manufacturing Agreement revenue of $7.1 million related to the sale of the Control Devices business, revenue improved 7.8% YoY. The North American commercial vehicle market and Stoneridge Brazil were the primary contributors to second quarter growth.
Gross margin decreased 277 basis points to 20.3% from 23.1% in the second quarter of 2025 as cost leverage on higher sales and benefits from targeted expense control initiatives were more than offset by a combination of higher material costs, stemming from unfavorable currency, strategic inventory-related actions and adverse product mix following the completion of a European regulatory retrofit campaign.
Consolidated net loss from continuing operations totaled $(5.3) million, or $(0.19) per share, compared to a net loss of $(11.1) million, or $(0.40) per share, for the quarter ended June 30, 2025.
Non-GAAP adjusted EBITDA totaled $5.5 million, or 3.0% of sales, compared to $0.8 million, or 0.5% of sales, in the year ago period.
Second Quarter GAAP Segment Results & Commentary
(in millions, except percentages and per share data)
Revenue
Three Months Ended June 30, 2026
Constant
%
Currency
2026
2025
Change
vs. 2025
Electronics
$ 160.9
$ 142.7
12.8 %
11.0 %
Stoneridge Brazil
20.5
14.9
37.6 %
25.7 %
Consolidated Net Sales
181.4
157.5
15.1 %
12.4 %
(in millions, except percentages and per share data)
Operating Income
Three Months Ended June 30, 2026
%
2026
2025
Change
Electronics
$ 4.9
$ 2.7
77.2 %
% of segment sales
3.0 %
1.9 %
110 bps
Stoneridge Brazil
2.6
1.0
165.8 %
% of segment sales
12.6 %
6.5 %
607 bps
Corporate
(8.6)
(7.9)
(9.0) %
Consolidated Operating Income
$ (1.2)
$ (4.2)
71.7 %
% of consolidated net sales
(0.7) %
(2.7) %
201 bps
Electronics second quarter sales of $160.9 million increased by $18.2 million, or 12.8%, relative to the second quarter of 2025. Excluding a favorable foreign currency translation impact of $2.6 million and Mexico Manufacturing Agreement revenue related to the sale of the Control Devices business, revenue improved 6.0% YoY. Revenue growth against the second quarter of 2025 was primarily driven by the North American commercial vehicle market. Second quarter adjusted operating margin increased by 12 basis points YoY to 3.0% as the benefits of a higher revenue base and implemented cost initiatives more than offset the cumulative impacts of unfavorable mix, currency and strategic inventory-related actions.
Stoneridge Brazil second quarter sales of $20.5 million increased by $5.6 million, or 37.6%. Excluding a favorable foreign currency translation impact of $1.8 million, sales improved by 25.7%. Higher OEM sales were the primary driver of growth during the quarter. Second quarter adjusted operating income of $2.3 million, or 11.2% of sales, increased 135.5%, or 464 basis points, compared to the second quarter of 2025 as higher sales volume more than offset increased SG&A expense.
Cash and Debt Balances
As of June 30, 2026, cash and cash equivalents totaled $71.5 million with total debt of $151.1 million, resulting in net debt of $79.6 million. The $38.5 million decrease in net debt compared to December 31, 2025 reflects the deployment of proceeds from the sale of the Control Devices business in January and tighter control of working capital during the first half of the year. The Company’s Credit Facility is due to mature on July 1, 2027. The company expects to refinance the credit facility, and is currently engaged in a global refinancing process.
2026 Outlook & Management Commentary
The Company is reaffirming the 2026 guidance ranges that were most recently updated in May. “We are encouraged by our progress in the second quarter, and believe initiatives to generate operational efficiencies and enhance profitability are beginning to materialize,” said Noblet. “We are also seeing promising signs across the European and North American commercial vehicle markets, which should support growth over the balance 2026. However, we believe it prudent to balance these positives against ongoing macroeconomic and geopolitical uncertainty. We continue to focus on material cost reductions, quality improvements as well as inflationary cost recovery, and remain committed to executing our long-term strategic plan as we navigate the challenging external environment.”
2026 FULL YEAR
GUIDANCE
(in millions, except percentages and per
share data)
2026
Current
Revenue ($M)
$645
—
$670
Adj. Gross Margin
21.5 %
—
22.0 %
Adj. Operating Margin
— %
—
0.5 %
Adj. EBITDA ($M)
$20
—
$25
%
3.1 %
—
3.7 %
The Company has not provided a reconciliation of its full-year 2026 guidance for adjusted gross margin, adjusted operating margin, and adjusted EBITDA (or adjusted EBITDA margin) to the most directly comparable GAAP financial measures because the Company is unable to provide such reconciliations without unreasonable effort. This is due to the inherent difficulty of forecasting with the required precision the timing and amount of various items that have not yet occurred, are out of the Company’s control, or cannot be reasonably predicted. For the same reasons, the Company is unable to address the probable significance of the unavailable reconciling information, which could be material to future results calculated in accordance with GAAP. The Company’s actual results calculated in accordance with GAAP may vary materially from these non-GAAP financial measures presented herein.
Conference Call on the Web
A live Internet broadcast of Stoneridge’s conference call regarding 2026 second quarter results can be accessed at 8:00 a.m. Eastern Time on Thursday, August 6, 2026, at www.stoneridge.com, which will also offer a webcast replay.
About Stoneridge, Inc.
Stoneridge, Inc., headquartered in Novi, Michigan, is a global supplier of safe and efficient electronic systems and technologies. Our systems and products power vehicle intelligence, while enabling safety and security for on- and off-highway transportation sectors around the world. Additional information about Stoneridge can be found at www.stoneridge.com.
Forward-Looking Statements
Statements in this press release contain “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. These statements appear in a number of places in this press release and may include statements regarding the intent, belief or current expectations of the Company, with respect to, among other things, our (i) future product and facility expansion, (ii) strategic focus following the sale of the Control Devices segment, (iii) acquisition strategy, (iv) investments and new product development, (v) growth opportunities related to awarded business, and (vi) operational expectations. Forward-looking statements may be identified by the words “will,” “may,” “should,” “could,” “would,” “designed to,” “believes,” “plans,” “projects,” “intends,” “expects,” “estimates,” “anticipates,” “continue,” and similar words and expressions. The forward-looking statements are subject to risks and uncertainties that could cause actual events or results to differ materially from those expressed in or implied by these statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, among other factors:
the ability of our suppliers to supply us with parts and components at competitive prices on a timely basis, including the impact of potential tariffs and trade considerations on their operations and output;fluctuations in the cost and availability of key materials and components (including semiconductors, printed circuit boards, resin, aluminum, steel and copper) and our ability to offset cost increases through negotiated price increases with or reimbursements from our customers or other cost reduction actions, as necessary;global economic trends, competition and geopolitical risks, including impacts from ongoing or potential global conflicts and any related sanctions and other measures, or an escalation of sanctions, tariffs or other trade tensions between the U.S. and other countries;tariffs specifically in countries where we have significant direct or indirect manufacturing or supply chain exposure and our ability to either mitigate the impact of tariffs or pass any incremental costs to our customers;our ability to achieve cost reductions that offset or exceed customer-mandated selling price reductions;the reduced purchases, loss, financial distress or bankruptcy of a major customer or supplier;the costs and timing of business realignment, facility closures or similar actions;a significant change in commercial, automotive, off-highway or agricultural vehicle production;competitive market conditions and resulting effects on sales and pricing;foreign currency fluctuations and our ability to manage those impacts;customer acceptance of new products;our ability to successfully launch/produce products for awarded business;adverse changes in laws, government regulations or market conditions affecting our products, our suppliers, or our customers’ products;our ability to protect our intellectual property and successfully defend against assertions made against us;liabilities arising from warranty claims, product recall or field actions, product liability and legal proceedings to which we are or may become a party, or the impact of product recall or field actions on our customers;labor disruptions at our facilities, or at any of our significant customers or suppliers;business disruptions due to natural disasters or other disasters outside of our control;the amount of our indebtedness and the restrictive covenants contained in the agreements governing our indebtedness, including our revolving credit facility;capital availability or costs, including changes in interest rates;refinancing risk and access to capital markets and liquidity;the failure to achieve the successful integration of any acquired company or business;risks related to a failure of our information technology systems and networks, and risks associated with current and emerging technology threats and damage from computer viruses, unauthorized access, cyber-attack and other similar disruptions;the items described in Part I, Item 1A (“Risk Factors”) in the Company’s most recent Form 10-K.
The forward-looking statements contained herein represent our estimates only as of the date of this filing and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, except as required by law, we specifically disclaim any obligation to do so, whether to reflect actual results, changes in assumptions, changes in other factors affecting such forward-looking statements or otherwise.
Use of Non-GAAP Financial Information
This press release contains information about the Company’s financial results that is not presented in accordance with accounting principles generally accepted in the United States (“GAAP”). Such non-GAAP financial measures are reconciled to their closest GAAP financial measures at the end of this press release. The provision of these non-GAAP financial measures for 2026 and 2025 is not intended to indicate that Stoneridge is explicitly or implicitly providing projections on those non-GAAP financial measures, and actual results for such measures are likely to vary from those presented. The reconciliations include all information reasonably available to the Company at the date of this press release and the adjustments that management can reasonably estimate.
In evaluating its business, the Company considers and uses net debt as a supplemental measure of its liquidity and the other non-GAAP financial measures as supplemental measures of its operating performance. Management believes the non-GAAP financial measures used in this press release are useful to both management and investors in their analysis of the Company’s financial position and results of operations. In particular, management believes that adjusted gross profit and margin, adjusted operating income (loss) and margin, adjusted income (loss) before tax, adjusted income tax expense (benefit), adjusted net loss from continuing operations, adjusted net income (loss), adjusted EPS, EBITDA, adjusted EBITDA, and net debt are useful measures in assessing the Company’s financial performance by excluding certain items that are not indicative of the Company’s core operating performance or that may obscure trends useful in evaluating the Company’s continuing operating activities. Management also believes that these measures are useful to both management and investors in their analysis of the Company’s results of operations and provide improved comparability between fiscal periods.
Adjusted gross profit and margin, adjusted operating income (loss) and margin, adjusted income (loss) before tax, adjusted income tax expense (benefit), adjusted net income loss from continuing operations, adjusted net income (loss), adjusted EPS, EBITDA, adjusted EBITDA, and net debt should not be considered in isolation or as a substitute for gross profit, operating income (loss), income (loss) before tax, income tax expense (benefit), loss from continuing operations, net income (loss), EPS, debt, cash and cash equivalents, cash provided by operating activities or other income statement or cash flow statement data prepared in accordance with GAAP. Because not all companies calculate non-GAAP financial measures in the same manner, the non-GAAP financial measures presented in this press release may not be comparable to similarly titled measures used by other companies, and the Company’s use of these measures may vary from that of other companies in its industry.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
June 30,
2026
December 31,
2025
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$ 71,514
$ 53,057
Accounts receivable, less reserves of $543 and $325, respectively
135,744
89,019
Inventories, net
112,999
106,422
Prepaid expenses and other current assets
24,025
26,956
Current assets of discontinued operations
—
86,342
Total current assets
344,282
361,796
Long-term assets:
Property, plant and equipment, net
61,117
62,659
Intangible assets, net
33,077
37,632
Goodwill
36,528
37,590
Operating lease right-of-use asset
8,486
9,570
Investments and other long-term assets, net
23,236
22,167
Long-term assets of discontinued operations
—
19,702
Total long-term assets
162,444
189,320
Total assets
$ 506,726
$ 551,116
LIABILITIES AND SHAREHOLDERS’ EQUITY
Accounts payable
$ 108,297
$ 62,398
Accrued expenses and other current liabilities
73,757
65,132
Current liabilities of discontinued operations
—
29,955
Total current liabilities
182,054
157,485
Long-term liabilities:
Revolving credit facility
151,089
180,942
Deferred income taxes
8,688
9,972
Operating lease long-term liability
5,776
6,601
Other long-term liabilities
9,994
11,604
Long-term liabilities of discontinued operations
—
4,733
Total long-term liabilities
175,547
213,852
Preferred Shares, without par value, 5,000 shares authorized, none issued
—
—
Common Shares, without par value, 60,000 shares authorized, 28,966 and 28,966
shares issued and 28,524 and 28,018 shares outstanding at June 30, 2026 and
December 31, 2025, respectively, with no stated value
—
—
Additional paid-in capital
204,854
219,186
Common Shares held in treasury, 442 and 948 shares at June 30, 2026 and
December 31, 2025, respectively, at cost
(9,649)
(27,457)
Retained earnings
43,957
77,150
Accumulated other comprehensive loss
(90,037)
(89,100)
Total shareholders’ equity
149,125
179,779
Total liabilities and shareholders’ equity
$ 506,726
$ 551,116
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Three months ended
June 30,
Six months ended
June 30,
(in thousands, except per share data)
2026
2025
2026
2025
Net sales
$ 181,384
$ 157,541
$ 342,231
$ 306,598
Costs and expenses:
Cost of goods sold
144,551
121,192
270,442
234,998
Selling, general and administrative
26,061
25,704
58,590
51,569
Design and development
11,960
14,841
23,365
28,533
Operating loss
(1,188)
(4,196)
(10,166)
(8,502)
Interest expense, net
2,404
3,233
6,089
6,475
Equity in (earnings) loss of investee
(222)
(50)
9
(344)
Other (income) expense, net
(649)
2,222
(179)
1,396
Loss before income taxes from continuing operations
(2,721)
(9,601)
(16,085)
(16,029)
Provision for income taxes from continuing operations
2,555
1,542
3,969
3,118
Loss from continuing operations
(5,276)
(11,143)
(20,054)
(19,147)
Discontinued operations:
Loss (gain) from discontinued operations, net of tax
—
(1,784)
3,322
(2,592)
Loss on disposal, net of tax
—
—
9,817
—
Loss (gain) from discontinued operations
—
(1,784)
13,139
(2,592)
Net loss
$ (5,276)
$ (9,359)
$ (33,193)
$ (16,555)
Loss per share from continuing operations:
Basic
$ (0.19)
$ (0.40)
$ (0.71)
$ (0.69)
Diluted
$ (0.19)
$ (0.40)
$ (0.71)
$ (0.69)
Loss per share from discontinued operations:
Basic
$ —
$ 0.06
$ (0.47)
$ 0.09
Diluted
$ —
$ 0.06
$ (0.47)
$ 0.09
Loss per share from Stoneridge Inc.:
Basic
$ (0.19)
$ (0.34)
$ (1.18)
$ (0.60)
Diluted
$ (0.19)
$ (0.34)
$ (1.18)
$ (0.60)
Weighted-average shares outstanding:
Basic
28,244
27,788
28,071
27,734
Diluted
28,244
27,788
28,071
27,734
Regulation G Non-GAAP Financial Measure Reconciliations
Exhibit 1 – Reconciliation of Adjusted Gross Profit
(USD in millions)
Q2 2025
Q2 2026
Gross Profit
$ 36.3
$ 36.8
Add: Pre-Tax Business Realignment Costs
—
—
Adjusted Gross Profit
$ 36.3
$ 36.8
Exhibit 2 – Reconciliation of Adjusted Operating Loss
Reconciliation of Adjusted Operating Loss
(USD in millions)
Q2 2025
Q2 2026
Operating Loss
$ (4.2)
$ (1.2)
Add: Pre-Tax Business Realignment Costs
1.4
—
Add: Pre-Tax Share-Based Compensation Accelerated Vesting
0.3
0.4
Add: Pre-Tax Brazilian Indirect Taxes
—
(0.3)
Adjusted Operating Loss
$ (2.5)
$ (1.0)
Exhibit 3 – Reconciliation of Q2 Adjusted Tax Rate
Reconciliation of Q2 2026 Adjusted Tax Rate
(USD in millions)
Q2 2026
Tax Rate
Loss Before Tax
$ (2.7)
Add: Pre-Tax Share-Based Compensation Accelerated Vesting
0.4
Add: Pre-Tax Brazilian Indirect Taxes
(0.5)
Adjusted Loss Before Tax
$ (2.8)
Income Tax Expense
2.6
(93.84) %
Add: Tax Impact from Pre-Tax Adjustments
(0.2)
Add: After-Tax Impact of Valuation Allowances, net
—
Adjusted Income Tax Expense on Adjusted Loss Before Tax
$ 2.4
(85.64) %
Exhibit 4 – Reconciliation of Adjusted Net Loss and EPS
Reconciliation of Q2 2026 Adjusted Net Income and EPS
(USD in millions, except EPS)
Q2 2026
Q2 2026 EPS
Net Loss
$ (5.3)
$ (0.19)
Add: After-Tax Share-Based Compensation Accelerated Vesting
0.4
0.02
Add: After-Tax Brazilian Indirect Taxes
(0.3)
(0.01)
Adjusted Net Loss
$ (5.2)
$ (0.18)
Exhibit 5 – Reconciliation of Adjusted EBITDA
Reconciliation of Adjusted EBITDA
(USD in millions)
Q2 2025
Q2 2026
Loss Before Income Taxes from Continuing Operations
$ (9.6)
$ (2.7)
Interest expense, net
3.2
2.4
Depreciation and amortization
5.5
5.6
EBITDA
$ (0.9)
$ 5.3
Add: Pre-Tax Business Realignment Costs
1.4
—
Add: Pre-Tax Share-Based Compensation Accelerated Vesting
0.3
0.4
Add: Pre-Tax Brazilian Indirect Taxes
—
(0.3)
Adjusted EBITDA
$ 0.8
$ 5.5
Exhibit 6 – Segment Adjusted Operating Income
Reconciliation of Electronics Adjusted Operating Income
(USD in millions)
Q2 2025
Q2 2026
Electronics Operating Income
$ 2.7
$ 4.9
Add: Pre-Tax Business Realignment Costs
1.4
—
Electronics Adjusted Operating Income
$ 4.2
$ 4.9
Reconciliation of Stoneridge Brazil Adjusted Operating Income
(USD in millions)
Q2 2025
Q2 2026
Stoneridge Brazil Operating Income
$ 1.0
$ 2.6
Add: Pre-Tax Brazilian Indirect Taxes
—
(0.3)
Stoneridge Brazil Adjusted Operating Income
$ 1.0
$ 2.3
Exhibit 7 – Reconciliation of Net Debt
(USD in millions)
Q2 2025
Q2 2026
Total Debt
$ 164.4
$ 151.1
Cash and Cash Equivalents
46.3
71.5
Net Debt
$ 118.1
$ 79.6
View original content to download multimedia:https://www.prnewswire.com/news-releases/stoneridge-reports-second-quarter-2026-results-302843860.html
SOURCE Stoneridge, Inc.
You may like
Technology
Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Published
12 minutes agoon
September 21, 2026By
– First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile –
– First global regulatory approval of obicetrapib marks a defining milestone for NewAmsterdam and Menarini, expanding treatment options for patients with elevated LDL-C –
FLORENCE, Italy, NAARDEN, Netherlands and MIAMI, Sept. 21, 2026 /PRNewswire/ — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, along with partner Menarini Group (“Menarini”), today announced that the European Commission (EC) has granted marketing authorization for Ubeslo® (obicetrapib 10 mg monotherapy) and Evlarco® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination) for patients with primary hypercholesterolaemia, both heterozygous familial (“HeFH”) and non-familial or mixed dyslipidaemia, marking the first regulatory approval of obicetrapib worldwide.
“The European Commission approval of Ubeslo and Evlarco marks a major milestone for NewAmsterdam as the first regulatory approval of obicetrapib globally, a novel oral therapy, and validates years of work focused on delivering a potential new treatment option for patients who continue to struggle to achieve recommended LDL-C levels despite previously available therapies,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma. “This first-in-class approval reflects the strength of the clinical evidence supporting obicetrapib, the dedication of our team and partners, and our commitment to addressing one of the largest unmet needs in cardiovascular medicine. Together with Menarini, we look forward to bringing Ubeslo and Evlarco to patients across Europe and building on this important milestone as we advance our vision of making obicetrapib available to patients around the world.”
The European Commission approval follows the positive opinion adopted by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) and is supported by data from NewAmsterdam’s comprehensive clinical development program evaluating obicetrapib, including the Phase 3 BROADWAY, BROOKLYN and TANDEM trials, which demonstrated statistically significant LDL-C reductions of up to 40% with obicetrapib monotherapy versus placebo and approximately 50% with obicetrapib combined with ezetimibe versus placebo, with a tolerability profile comparable to placebo. NewAmsterdam and Menarini continue to advance the clinical development of obicetrapib through multiple ongoing Phase 3 trials, including PREVAIL, a cardiovascular outcomes trial, as well as REMBRANDT and RUBENS.
“This approval represents an important advancement for patients across Europe who require additional LDL-C lowering despite available therapies,” said Elcin Barker Ergun, Chief Executive Officer of Menarini Group. “We are proud to reach this significant achievement alongside NewAmsterdam and look forward to leveraging our well-established commercial capabilities and deep cardiovascular expertise to bring Ubeslo and Evlarco to healthcare providers and eligible patients throughout Europe.”
Under the parties’ licensing agreement, Menarini holds exclusive commercialization rights for obicetrapib in Europe and is responsible for regulatory interactions and commercialization activities throughout the region. NewAmsterdam is entitled to tiered double-digit percentage royalties ranging from the low double-digits to mid-twenties on net sales in the Menarini Territory and up to an additional €833 million upon the achievement of various clinical, regulatory and commercial milestones.
For full details on the approved indications, contraindications, warnings, and precautions please refer to the Summary of Product Characteristics (SmPC) which will be made available on the European Medicines Agency websites at:
https://www.ema.europa.eu/en/medicines/human/EPAR/ubeslo
https://www.ema.europa.eu/en/medicines/human/EPAR/evlarco
About Obicetrapib
Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of Major Adverse Cardiovascular Events (“MACE”). The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.
About Cardiovascular Disease
Cardiovascular disease remains the leading cause of death globally, despite the availability of lipid-lowering therapies (“LLTs”). By 2050 more than 184 million U.S. adults are expected to be affected by CVD and hypertension, including 27 million with coronary heart disease and 19 million with stroke. In the United States from 2019 through 2022, CVD age-adjusted mortality rates increased by 9%, reversing the trend observed since 2010 and undoing nearly a decade of progress. Despite the availability of high-intensity statins and non-statin LLTs, LDL-C target level attainment remains low, contributing to residual cardiovascular risk, and underscoring a significant clinical need for improved therapeutic regimens. Even with 269 million LLT prescriptions written over the last 12 months, 30 million under-treated US adults are not at their risk-based LDL-C goal, of which 13 million have ASCVD. Less than 1 in 4 patients with ASCVD achieve an LDL-C goal of less than 70 mg/dL and only 10% of very high risk ASCVD patients achieve the goal below 55 mg/dL. In addition to the 30 million under-treated U.S. adults, there are 10 million patients diagnosed with elevated LDL-C who are not taking any LLTs including statins. Beyond LDL-C, additional factors are at play, such as lifestyle choices, tobacco use, and obesity, as well as inflammation, thrombosis, triglyceride levels, elevated Lp(a) levels, and type 2 diabetes.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company dedicated to build a new standard of care for people living with cardiometabolic disease. The Company is advancing therapies designed to address a significant unmet need for safe, well-tolerated, and convenient treatment options that lower LDL-C while advancing innovation beyond a single marker to better address cardiovascular risk. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose, once-daily CETP inhibitor, alone and as a fixed-dose combination with ezetimibe, in patients at risk of cardiovascular disease with elevated LDL-C. Guided by its mission, the Company challenges convention with courage, translates deep biological insight into meaningful patient impact, and delivers with rigor, precision, and purpose.
About Menarini Group
The Menarini Group, with headquarters in Florence, is present in 140 countries worldwide to date, with $5.5 billion in consolidated turnover and more than 17,000 employees. Menarini’s products are present in the most important treatment areas, including those of cardiometabolic, oncology, gastroenterology, diabetology, pneumology, and anti-inflammatory/analgesic products. Through its commitment to R&D and high-quality manufacturing activities, Menarini continuously contributes to patients’ health worldwide, maintaining the highest quality standards.
Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and are subject to the “safe harbor” provisions created thereunder. All statements that are not historical facts are hereby identified as forwarding-looking statements for this purposes and include, among others, statements relating to: the therapeutic potential of obicetrapib; expected availability of Ubeslo and Evlarco across Europe; the Company’s licensing agreement with Menarini and entitlement to potential future payments thereunder; the continued advancement of clinical development of obicetrapib through multiple ongoing Phase 3 trials; and other statements regarding the Company’s future operations, prospects, objectives, strategies and other future events. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These forward-looking statements are based upon management’s current expectations and assumptions. Actual results or events could differ materially and adversely from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various risks, uncertainties and other factors, including, among others: whether projections regarding clinical outcomes will reflect actual results in clinical use of Ubeslo and Evlarco; risks related to the Company’s ability to achieve its business plans, objectives and milestones, including those related to its licensing agreement with Menarini; challenges inherent to the clinical development and launch of new drug products; risks related to the Company’s reliance on third parties; and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, that are described in greater detail in the sections entitled “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 18, 2026 and in its Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026, as well as in other filings the Company may make with the SEC in the future, which are available at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date of this press release, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of new information, future events, changed circumstances or otherwise, except as otherwise required by law.
BROADWAY (NCT05142722)
BROOKLYN (NCT05425745)
OCEAN NCT04770389
PREVAIL (NCT05202509)
REMBRANDT (NCT06305559)
ROSE NCT04753606
ROSE2 NCT05266586
RUBENS (NCT07219602)
TANDEM (NCT06005597)
TULIP NCT01970215
(Translations: in the event of any discrepancy, the English language version prevails)
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/menarini-group-and-newamsterdam-pharma-receive-european-commission-approval-for-ubeslo-obicetrapib-monotherapy-and-evlarco-obicetrapib-plus-ezetimibe-fixed-dose-combination-302884871.html
Technology
Georgia Power furthers partnership with statewide nonprofit to make Georgia State Parks more accessible and enjoyable
Published
12 minutes agoon
September 21, 2026By
Company joins with Friends of Georgia State Parks for annual volunteer effort on September 26; New $10,000 donation to kickstart “Georgia in Color” initiative for color accessibility glasses
ATLANTA, Sept. 21, 2026 /PRNewswire/ — Georgia Power, the state’s leading electric utility serving customers in all but four Georgia counties, is proud to continue its longstanding partnership with Friends of Georgia State Parks & Historic Sites (Friends) – a nonprofit organization with a mission to serve, support, and celebrate Georgia State Parks & Historic Sites.
This Saturday, September 26, hundreds of Georgia Power volunteers are expected to deploy for Your State Parks Day, an annual event hosted by Friends to clean up, beautify and care for Georgia’s state parks in celebration of National Public Lands Day. Fellow Georgians are also invited to join the volunteer event, or support the program in other ways by donating to Friends or simply sharing their favorite state parks memory. All of the information, including event and registration details by local state park, is available on the Friends of Georgia State Parks & Historic Sites website.
Georgia Power is also donating $10,000 to help kickstart a new fundraising effort by Friends to place free EnChroma color accessibility glasses in all Georgia State Parks for visitor use. For many people with red-green color vision deficiency, the vibrant colors of fall foliage, spring wildflowers, and Georgia’s scenic landscapes may appear less distinct. EnChroma glasses use specialized optical filters designed to enhance color contrast, helping many people distinguish certain colors more easily. Georgia Power’s donation follows a $25,000 donation at the end of 2025 to Friends to develop the program, and previous work with the Aimee Copeland Foundation to place all-terrain Trackchairs in Georgia State Parks for visitor use.
“Georgia’s state parks are a tremendous natural resource and asset for our state, driving travel and tourism for local communities and hosting millions of visitors each year,” said Trey Kilpatrick, senior vice president of External Affairs. “At Georgia Power, we’re committed to making our communities better because we are here. We’re excited to help more visitors enjoy a full experience through the Georgia in Color initiative, and to continue to partner with Friends of Georgia State Parks to protect and care for these special places so they can be enjoyed by Georgians and visitors from around the world for generations to come.”
“Georgia in Color is about helping more visitors fully experience the natural beauty of Georgia’s state parks,” said Damon Kirkpatrick, president and CEO of Friends of Georgia State Parks & Historic Sites. “Georgia Power’s generous investment in this initiative, together with the hands-on service of its volunteers, demonstrates a meaningful commitment to making these treasured places more accessible, welcoming, and enjoyable for everyone.”
Friends is a nonprofit organization with a mission to serve, support, and celebrate Georgia State Parks & Historic Sites. Statewide, Friends works to raise awareness of the economic and intrinsic values of Georgia’s greatest treasures. The organization works with state and community leaders to help make sure that Georgia’s natural and cultural resources are well protected, well maintained and well preserved for generations to come. At the local level, more than 50 chapters work with their respective sites to support individual projects and programs, with thousands of hours of volunteer time donated each year.
To learn more about Friends of Georgia State Parks & Historic Sites, and the organization’s Your State Parks Day program, visit: https://friendsofgastateparks.org/.
About Georgia Power
Georgia Power is the largest electric subsidiary of Southern Company (NYSE: SO), America’s premier energy company. Value, Reliability, Customer Service and Stewardship are the cornerstones of the company’s promise to 2.8 million customers in all but four of Georgia’s 159 counties. Committed to delivering clean, safe, reliable and affordable energy, Georgia Power maintains a diverse, innovative generation mix that includes nuclear, coal and natural gas, as well as renewables such as solar, hydroelectric and wind. Georgia Power offers rates below the national average, focuses on delivering world-class service to its customers every day and the company is recognized by J.D. Power as an industry leader in customer satisfaction. For more information, visit www.GeorgiaPower.com and connect with the company on Facebook (Facebook.com/GeorgiaPower), X (X.com/GeorgiaPower) and Instagram (Instagram.com/ga_power).
View original content to download multimedia:https://www.prnewswire.com/news-releases/georgia-power-furthers-partnership-with-statewide-nonprofit-to-make-georgia-state-parks-more-accessible-and-enjoyable-302884857.html
SOURCE Georgia Power
Technology
HOIN Launches HOP-HQ400 Industrial-Grade, Drop-Resistant and Water-Resistant 4-Inch Portable Thermal Printer
Published
12 minutes agoon
September 21, 2026By
Dual-Mode Label and Receipt Printing for Demanding Mobile Workflows
SHENZHEN, China, Sept. 21, 2026 /PRNewswire/ — HOIN today announced the launch of the HOP-HQ400, an industrial-grade 4-inch portable thermal printer designed for mobile printing in demanding work environments. Combining dual-mode label and receipt printing with a rugged protective design, flexible connectivity and broad system compatibility, the HOP-HQ400 is built to support logistics, warehousing, delivery, retail and outdoor field operations.
One Printer for Labels and Receipts
The HOP-HQ400 supports both label and receipt printing, allowing users to switch modes according to the task at hand. Receipt printing supports widths of 58mm, 80mm and 104mm, while label printing supports widths from 20mm to 108mm. This flexible media range helps businesses handle different ticket, label and on-site printing requirements with one portable device.
From warehouse identification and logistics operations to courier documents, food-delivery orders, supermarket receipts and outdoor field work, the HOP-HQ400 is designed to simplify mobile printing workflows and reduce the need to switch between devices.
Rugged Protection for Challenging Field Conditions
To help withstand the demands of mobile operations, the HOP-HQ400 features a protective edge-wrapped design and a drop-resistant structure. It supports a 1.5-meter drop resistance rating and an IP56 water-resistance rating, providing added protection against accidental drops and wet working conditions.
“Portable printers get used in ways desktop printers never do,” said Nina Xia, co-founder of HOIN. “The HOP-HQ400 came out of conversations with customers in outdoor delivery and logistics who needed hardware that could handle the environment, not just the print job.”
Fast Output and Flexible Connectivity
The HOP-HQ400 uses an imported Japanese print mechanism and delivers print speeds of up to 100mm/s. A high-power 5200 battery and Type-C interface support mobile use and convenient charging.
The printer offers a range of connectivity options, including USB, Bluetooth, LAN and Wi-Fi. It supports Windows, Android, iOS, Mac and Linux systems, helping customers integrate the device into different terminals and business workflows.
The HOP-HQ400 also supports automatic paper detection and positioning, as well as 1D and 2D barcode printing, helping users improve printing accuracy and on-site processing efficiency.
A 0.96-Inch Display for Easier Setup
A 0.96-inch display enables users to adjust print density, calibrate paper and change interface modes directly on the device. These controls help simplify configuration and reduce operating steps in complex field environments.
Command-Set Compatibility for Customer Integration
For customers that need to integrate the printer into existing software or develop customized applications, the HOP-HQ400 supports TSPL, CPCL and ESC/POS command sets. This compatibility helps customers connect the printer with established systems and adapt it to different application scenarios.
Designed for Multi-Industry Mobile Printing
With dual-mode printing, industrial-grade protection, multiple connectivity options and broad operating-system compatibility, the HOP-HQ400 is designed for applications including:
Logistics and warehousing: on-site labels, cargo identification and work documents.Courier and food delivery: mobile waybills, order receipts and delivery-related information.Supermarkets and retail: receipts and labels in different supported widths.Outdoor and high-altitude operations: on-site printing in mobile, complex or wet environments.
About HOIN
Shenzhen Hoin Electronic Technology Co., Ltd.(HOIN) is a manufacturer of Thermal Printer, Thermal Label Printer, Thermal Transfer Printer, Thermal Barcode Label Printer, Barcode Printer, and portable printing solutions. Established in 2015 and operating from a 10,000㎡ facility in Baoan, Shenzhen, the company serves clients across more than 50 countries in telecom, logistics, retail, and industrial sectors. Certifications include ISO9001:2015, CE, FCC, BSCI, RoHS, CCC, CB, and BIS.
Media Contact:
Person: Nina Xia
Email: nina.xia@hoinprinter.com
Company: Shenzhen Hoin Electronic Technology Co., Ltd.
Official Website: https://www.hoinprinter.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoin-launches-hop-hq400-industrial-grade-drop-resistant-and-water-resistant-4-inch-portable-thermal-printer-302884535.html
SOURCE Shenzhen Hoin Electronic Technology Co., Ltd.
Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Georgia Power furthers partnership with statewide nonprofit to make Georgia State Parks more accessible and enjoyable
HOIN Launches HOP-HQ400 Industrial-Grade, Drop-Resistant and Water-Resistant 4-Inch Portable Thermal Printer
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology4 days agoMagentic raises $18M to build the AI workforce for the physical world
-
Technology3 days agoPeoplevine Secures Multi-Million-Dollar Growth Investment to Accelerate AI-Powered Hospitality
-
Technology5 days agoAristotle Secures $5M to Replace the Chatbot with High-Dosage AI Tutoring for Students
-
Technology3 days ago
Saturday, September 19, 2026
-
Technology3 days ago4Humanity Introduces the National Positivity Portal, Using AI to Make the Good Happening Across America Easier to See
-
Technology4 days agodtcpay Welcomes SBI Group as Strategic Investor, Extending Series A to US$25M
-
Technology4 days agoInsider One Introduces Agent One™, the Self-Optimizing Intelligence System for Autonomous Customer Engagement
-
Technology5 days agoBlockboard Named Finalist in Two Categories at the 2026 Digiday Technology Awards
